Display options
Cite
Signoretti M, Bruno MJ, Zerboni G, et al. Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. United European Gastroenterol J. 2018;6(4):489-499doi: 10.1177/2050640617752182.
Signoretti, M., Bruno, M. J., Zerboni, G., Poley, J. W., Delle Fave, G., & Capurso, G. (2018). Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. United European gastroenterology journal, 6(4), 489-499. https://doi.org/10.1177/2050640617752182
Signoretti, Marianna, et al. "Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis." United European gastroenterology journal vol. 6,4 (2018): 489-499. doi: https://doi.org/10.1177/2050640617752182
Signoretti M, Bruno MJ, Zerboni G, Poley JW, Delle Fave G, Capurso G. Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. United European Gastroenterol J. 2018 May;6(4):489-499. doi: 10.1177/2050640617752182. Epub 2018 Jan 08. PMID: 29881603; PMCID: PMC5987280.
Copy Download .nbib Format: NLM
Share it on

United European Gastroenterol J. 2018 May;6(4):489-499. doi: 10.1177/2050640617752182. Epub 2018 Jan 08.

Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis.

United European gastroenterology journal

Marianna Signoretti, Marco J Bruno, Giulia Zerboni, Jan-Werner Poley, Gianfranco Delle Fave, Gabriele Capurso

Affiliations

  1. Digestive and Liver Disease Unit, S. Andrea Hospital, Rome, Italy.
  2. Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.

PMID: 29881603 PMCID: PMC5987280 DOI: 10.1177/2050640617752182

Abstract

BACKGROUND: Data on surveillance for pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals (HRIs) with "familial pancreatic cancer" (FPC) and specific syndromes are limited and heterogeneous.

OBJECTIVE: We conducted a systematic review and meta-analysis of PDAC surveillance studies in HRIs.

METHODS: Prevalence of solid/cystic pancreatic lesions and of lesions considered a successful target of surveillance (proven resectable PDAC and high-grade precursors) was pooled across studies. The rate of lesions diagnosed by endoscopic ultrasonography (EUS)/magnetic resonance imaging (MRI) and across different HRI groups was calculated.

RESULTS: Sixteen studies incorporating 1588 HRIs were included. The pooled prevalence of pancreatic solid and cystic lesions was 5.8% and 20.2%, respectively. The pooled prevalence of patients with lesions considered a successful target of surveillance was 3.3%, being similar to EUS or MRI and varying across subgroups, being 3% in FPC, 4% in hereditary pancreatitis, 5% in familial melanoma, 6.3% in hereditary breast/ovarian cancer, and 12.2% in Peutz-Jeghers syndrome. The pooled estimated rate of lesions considered a successful target of surveillance during follow-up was 5/1000 person-years.

CONCLUSION: Surveillance programs identify successful target lesions in 3.3% of HRIs with a similar yield of EUS and MRI and an annual risk of 0.5%. A higher rate of target lesions was reported in HRIs with specific DNA mutations.

Keywords: Pancreatic cancer; family history; meta-analysis; screening

References

  1. JAMA Surg. 2015 Jun;150(6):512-8 - PubMed
  2. Phys Ther. 2009 Sep;89(9):873-80 - PubMed
  3. Am J Gastroenterol. 2009 Sep;104(9):2175-81 - PubMed
  4. Dig Liver Dis. 2010 Sep;42(9):597-605 - PubMed
  5. Clin Cancer Res. 2010 Oct 15;16(20):5028-37 - PubMed
  6. Stat Med. 2002 Jun 15;21(11):1539-58 - PubMed
  7. Gut. 2009 Oct;58(10):1410-8 - PubMed
  8. Clin Cancer Res. 2013 Jan 15;19(2):442-9 - PubMed
  9. Br J Surg. 2008 Mar;95(3):357-62 - PubMed
  10. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  11. Cancer Res. 2014 Jun 1;74(11):2913-21 - PubMed
  12. Pancreatology. 2016 Jul-Aug;16(4):584-92 - PubMed
  13. Am J Gastroenterol. 2011 May;106(5):946-54 - PubMed
  14. Gastrointest Endosc. 2002 Oct;56(4 Suppl):S82-6 - PubMed
  15. Gastroenterology. 2012 Apr;142(4):796-804; quiz e14-5 - PubMed
  16. Pancreas. 2017 Jan;46(1):28-34 - PubMed
  17. Eur J Cancer. 2015 Sep;51(14):1911-7 - PubMed
  18. J Clin Oncol. 2016 Jun 10;34(17 ):2010-9 - PubMed
  19. Gastroenterology. 2011 Mar;140(3):850-6 - PubMed
  20. Am J Cancer Res. 2017 Feb 01;7(2):357-369 - PubMed
  21. World J Gastrointest Endosc. 2015 Jul 25;7(9):833-42 - PubMed
  22. Pancreas. 2014 Apr;43(3):458-61 - PubMed
  23. Pancreas. 2014 Aug;43(6):917-21 - PubMed
  24. Gut. 2016 Sep;65(9):1505-13 - PubMed
  25. Gastrointest Endosc. 2015 Nov;82(5):812-8 - PubMed
  26. Neuroendocrinology. 2016;103(2):153-71 - PubMed
  27. Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 - PubMed
  28. J Gastrointest Surg. 2012 Apr;16(4):771-83 - PubMed
  29. Gut. 2013 Mar;62(3):339-47 - PubMed

Publication Types